[{"address1": "1 Commonwealth Lane, No. 08-22", "city": "Singapore", "zip": "149544", "country": "Singapore", "phone": "65 6250 7738", "website": "https://w2.cytomed.sg", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Chee Kong  Choo", "age": 65, "title": "Executive Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 27316, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wee Kiat  Tan Ph.D.", "age": 36, "title": "Co-CEO, COO & Director", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 88130, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jieming  Zeng M.D., Ph.D.", "age": 49, "title": "Chief Scientific & Medical Officer and Director", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 89742, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Goh", "age": 33, "title": "Chief Financial Officer", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tien Wee  Luk M.D.", "age": 37, "title": "Chief Clinical Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yoong Ying  Tan", "age": 34, "title": "Chief Corporate Officer", "yearBorn": 1989, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.46, "open": 1.54, "dayLow": 1.57, "dayHigh": 1.57, "regularMarketPreviousClose": 1.46, "regularMarketOpen": 1.54, "regularMarketDayLow": 1.57, "regularMarketDayHigh": 1.57, "forwardPE": -9.235294, "volume": 468, "regularMarketVolume": 468, "averageVolume": 66728, "averageVolume10days": 1080, "averageDailyVolume10Day": 1080, "marketCap": 18117800, "fiftyTwoWeekLow": 1.36, "fiftyTwoWeekHigh": 5.5, "priceToSalesTrailing12Months": 35.683506, "fiftyDayAverage": 1.70724, "twoHundredDayAverage": 2.41443, "currency": "USD", "enterpriseValue": 9338999, "floatShares": 3546127, "sharesOutstanding": 11540000, "sharesShort": 125588, "sharesShortPriorMonth": 131617, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0109, "heldPercentInsiders": 0.69271004, "heldPercentInstitutions": 0.00042, "shortRatio": 20.68, "shortPercentOfFloat": 0.073699996, "impliedSharesOutstanding": 11688900, "bookValue": 0.975, "priceToBook": 1.6102564, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -4132896, "trailingEps": -0.3, "forwardEps": -0.17, "enterpriseToRevenue": 18.393, "enterpriseToEbitda": -2.696, "52WeekChange": -0.57300276, "SandP52WeekChange": 0.31472707, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GDTC", "underlyingSymbol": "GDTC", "shortName": "CytoMed Therapeutics Limited", "longName": "CytoMed Therapeutics Limited", "firstTradeDateEpochUtc": 1681479000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5fbb5a07-c64c-3457-b39c-0446de45b69d", "messageBoardId": "finmb_647650276", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.57, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 8995067, "totalCashPerShare": 0.779, "ebitda": -3463885, "totalDebt": 448022, "quickRatio": 12.832, "currentRatio": 14.083, "totalRevenue": 507736, "debtToEquity": 3.984, "revenuePerShare": 0.048, "returnOnAssets": -0.27299, "returnOnEquity": -0.69873, "freeCashflow": -2043202, "operatingCashflow": -3432830, "revenueGrowth": -0.228, "grossMargins": 0.99266, "operatingMargins": -8.11267, "financialCurrency": "SGD", "trailingPegRatio": null, "__fetch_time": "2024-09-23"}]